NanoVibronix raises $10M in public offering of Series G preferred and warrants

ENvue Medical, Inc.

Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.
Preferred pays 9% cumulative dividend, convertible at $2.04/share, subject to full-ratchet anti-dilution and 4.99%/9.99% beneficial ownership cap.
Use of proceeds: repay $1.3M debenture (Feb 2025) and up to $700k on $2.5M note (Jan 2025); remainder for general corporate purposes.
Amended Series X preferred: increased authorized shares from 57,720 to 62,220 and cut conversion price to match Series G price.
Dawson James Securities acted as sole bookrunner; offering closed May 16, 2025.

item 1.01item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.